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QOL, were $1.90 (D); $2.54 (D  I) for ICS compared to
$2.61 (D); $3.06 (D  I) for LTRA. The cost-effectiveness
ratios were in favor of ICS for both effectiveness parameters
even after a rigorous sensitivity analysis was performed.
CONCLUSION: Based on SFD and QOL, this analysis
shows that from the perspective of third-party payers ICS
is more cost-efficacious than LTRA with and without the
consideration of indirect costs in patients with persistent
asthma.
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OBJECTIVES: To determine if there were significant differ-
ences in pulmonary status (as measured by forced expira-
tory flow in 1 second [FEV1]) between care sites and subse-
quently to characterize the associations between these
outcomes and practice patterns, including antibiotic use.
METHODS: The Epidemiologic Study of Cystic Fibrosis
contains detailed information on clinical status and ther-
apies collected at physician encounters on more than
20,000 CF patients. Comparisons were done separately
for four different age groups ( 6, 6–12, 13–17,  18).
For each age group, sites were included if 10 or more pa-
tients in the age group had been followed from January
1995 to December 1996. For each site and age group,
lung health was defined as the median of FEV1 values for
the patients at that site. For each age group, the median
values at eligible centers were ranked in order from the
highest to lowest value. The mean FEV1 for all patients in
the 25% of centers reporting the highest median values
was compared to the mean values for the patients in 25%
of centers with the lowest ranked medians.
RESULTS: Large differences were observed between the
centers ranked in the upper 25% compared to the lower
25% (6–12 years; 92.3% versus 74.6%, p  0.001. 13–
17 years; 84.6% versus 64.0%, p  0.001.  18 years;
64.4% versus 49.7% p  0.001). Sites that reported
higher values for FEV1 monitored patients more fre-
quently, reviewed spirometry more often, and treated pa-
tients more aggressively as indicated by the frequency of
antibiotic interventions, the use of intravenous antibiot-
ics, and the duration of therapy.
CONCLUSIONS: Frequent monitoring and aggressive
intervention is associated with a better outcome in cystic
fibrosis patients.
RD4
RELATIONSHIP AMONG DISEASE-SPECIFIC 
QUALITY OF LIFE AND CLINICAL 
CONSEQUENCES OF ASTHMA
Kozma CM1, Slaton TL1, Watrous ML2
1University of South Carolina, Columbia, SC, USA; 
2Genentech, Inc., South San Francisco, CA, USA
OBJECTIVE: To use canonical correlation analysis to in-
vestigate the relationships among disease-specific quality
of life domains measured by the Asthma Quality of Life
Questionnaire (AQLQ) and selected clinical variables.
METHODS: Canonical correlation analysis was con-
ducted using data from the final visit of a clinical trial.
Canonical correlation is a technique for analyzing rela-
tionships among sets of variables. Two sets of variables
were used: 1) domains of the AQLQ, and 2) clinical vari-
ables including -agonist use, FEV1, self-reported symp-
toms (four variables), PEFR, and oral steroid use. Since
the overall AQLQ score is a linear combination of the
domain scores, two separate models were run (overall,
and domain score models).
RESULTS: Analysis of the overall AQLQ score and the
set of clinical variables resulted in a canonical correlation
of rc  0.76 (p  0.0001). The clinical variate (i.e., a
composite of all the clinical variables) accounted for 57%
of the variance in the overall AQLQ score. Similar results
were obtained from the four AQLQ domain scores and
the clinical variate. The first canonical variate was signif-
icant with rc  0.79 (p  0.0001) resulting in the clinical
variate explaining 45% of the variance in the AQLQ do-
mains. The four self-reported symptom variables were
most highly correlated with the AQLQ variates (all 
0.7), and the symptom domain was most highly corre-
lated with the clinical variate (0.79). The remainder of
the correlations ranged from 0.18 to 0.27. These results
were stable across all assessments in the clinical trial.
CONCLUSIONS: This analysis provides evidence of con-
struct validity for the AQLQ and supports the use of ca-
nonical correlation analysis for validity assessment. These
results suggest that the AQLQ captures a unique aspect of
asthma because AQLQ scores are more highly correlated
with self-reported rather than traditional clinical measures.
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Randomized clinical trials (RCTs) are considered the gold
standard to demonstrate treatment efficacy. However, if
patients are heterogeneous with respect to treatment
